Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer- Karim Fizazi

The following presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.

Karim Fizazi, MD presents, “Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer” and discusses mechanisms of resistance to ADT with CRPC, mechanisms of CRPC resistance to new drugs and mechanisms of resistance to taxanes.  Also, AR-V7 seems a promising predictor of treatment resistance and AR signaling remains key and may be targeted with novel agents.

Additonal related content: 
Biography:
Karim Fizazi, MD, PhD is a medical oncologist, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France and Professor in Oncology at the University of Paris. Dr. Fizazi received his medical degree in 1995 and completed a fellowship in 1997, both in medical oncology. He obtained a PhD in Molecular Oncology in 2003.

Dr. Fizazi has been involved in many Phase I, II and III clinical trials as a national or global coordinating investigator. These include GETUG 12 (a 400 patient national Phase III trial testing docetaxel in high-risk localized prostate cancer), GETUG 13 (an international trial in poor-prognosis non-seminomatous germ-cell tumors), and numerous industry-sponsored clinical trials, including the denosumab versus zoledronic acid pivotal study, the TAK700 post-docetaxel and the cabazitaxel-OGX-011 large Phase III trials in castrate-resistant prostate cancer, and the abiraterone Latitude Phase III trial in patients with hormone-naïve metastatic prostate cancer.